Teva Canada Announces the Launch of (Pr)Teva-Abacavir/Lamivudine Tablets, a Generic of (Pr)Kivexa®

- Health
  0

(Pr)Teva-Abacavir/Lamivudine is available as 600 mg/300 mg tablets in bottles of 30 tablets and blisters of 30 tablets. (CNW Group/Teva Canada Limited)TORONTO, March 15, 2016 /CNW/ – Teva Canada Limited, a subsidiary of
Teva Pharmaceutical Industries Ltd., announced that Health Canada has
approved its application for the generic version of PrKivexa®. This agent is indicated in antiretroviral combination therapy
for the…